euro adhoc: LION bioscience AG
Mergers - Acquisitions - Takeovers
LION
bioscience AG confirms receipt of adjustment of take-over bid from DH-
Capital GmbH & Co. KG und OH Beteiligungen GmbH & Co. KG
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
20.10.2006
Heidelberg, October 20, 2006 - LION bioscience AG received today an adjustment of the voluntary take-over bid to the LION shareholders by the two investment- companies of the Hopp family, DH-Capital GmbH & Co. KG und OH Beteiligungen GmbH & Co. KG. The management and supervisory board of LION bioscience AG will release a qualified statement regarding this adjustment within the next days.
The take-over bid, dated August 15, 2006 is to be seen against the background of the acquisition of SYGNIS Bioscience GmbH & Co. KG, formerly owned by the majority of the investment-company of the Hopp familiy, by LION bioscience AG. The bid was originally made under the condition, that the two investment companies could control more than 30% of the voting rights of LION bioscience AG until October 24, 2006. Close to the end of this deadline, it seems to be uncertain, that this condition will be reached. Therefore, the bidders are waiving this condition. As a result of this, the term of acceptance is extended until November 7, 2006.
end of announcement euro adhoc 20.10.2006 17:35:18
Further inquiry note:
Peter Willinger
Vorstand Finanzen
Telefon: +49(0)6221 4038 293
E-Mail: peter.willinger@lionbioscience.com
Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
New York / ADR
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade